Aug. 20 at 3:56 PM
Piper Sandler (Aug. 18)🏁
$NUVL at an Overweight/
$112.
$RHHBY $PFE TAK NVS ABBV
LLY JNJ
$ZLAB $NUVB
Piper Sandler said in its initiation report:
Investors largely view
$NUVL as a high quality precision oncology company but seem to be in a waiting pattern until we get closer to the 1L ALK data in a few years.
We think the Street underestimates the near-term value creation over the next 18 months as we get
(1) updated Ph II neladalkib data in 2L+ ALK NSCLC later this year which will confirm the degree of differentiation vs. lorlatinib, and by indirect comparison vs. alectinib,
(2) initial commercial sales from zidesamtinib in 2026 in the ROS1 market which we think investors undervalue, and
3) potential initial data for NVL-330 in HER2+ NSCLC next year, in our view.
